semaglutide and addiction GLP‑1 Drugs May Be the Next Tool in the Fight Against | Health News Patients on Ozempic started reporting
Description
Some UHC plans may require step therapy
Recent studies examining patients taking semaglutide found that those using the drug had significantly higher odds of developing nonarteritic anterior ischemic optic neuropathy, or NAION, a rare condition that can cause sudden vision loss
In the SURMOUNT 1 trial, tirzepatide 15 mg/wk with general nutritional instructions produced a 20.9 % reduction in body weight from baseline (versus 3.1 % with general nutrition instructions alone) [15], whereas in the SURMOUNT 3 trial, tirzepatide 10 or 15 mg/wk started after 12 weeks of intensive lifestyle intervention produced a 25 % reduction from baseline (versus 4.8 % with intensive lifestyle intervention alone) [170]
This peptide is still experimental, and its risk profile is less characterized
Elsevier B.V
Do not adjust your dose or dosing schedule without explicit guidance from your prescribing clinician
